DailyDoctor Archive Specialties Get app
Back to the 17 September 2026 edition

Research · 04 of 06

One subconjunctival triamcinolone injection controlled post-phaco inflammation as well as six weeks of drops

For patients who cannot manage a post-phaco drop taper, a single subconjunctival triamcinolone injection is a reasonable alternative; check pressure at follow-up.

Design
Randomised controlled trial
Population
100 eyes having phacoemulsification for age-related cataract in India
Primary outcome
Anterior chamber cells and flare to day 42
Effect
No significant difference; IOP spikes >25 mmHg 4 vs 3 (p = 0.69)

This randomised trial from India enrolled 100 eyes having phacoemulsification for age-related cataract under peribulbar anaesthesia. Half received subconjunctival triamcinolone acetonide 20 mg at the end of surgery; half received tapering topical prednisolone 1% for six weeks.

Anterior chamber cells, flare and mean intraocular pressure did not differ at any visit through day 42. Pressure spikes above 25 mmHg occurred in four eyes with triamcinolone and three with drops (p = 0.69). Central subfoveal thickness on OCT at day 42 was similar. Subconjunctival haemorrhage was more common with the injection at days 1 and 7, resolving by day 21, and a few patients noticed a visible steroid deposit.

For elderly patients who struggle with drop schedules, and for high-volume and outreach cataract services where follow-up is uncertain, a single depot removes an adherence problem. The trial was small and not powered to detect differences in rare events such as steroid-induced pressure rise or cystoid macular oedema.

  • Consider depot subconjunctival triamcinolone for patients unlikely to manage a drop taper
  • Warn patients about subconjunctival haemorrhage and a visible deposit
  • Check intraocular pressure at follow-up, particularly in known steroid responders or glaucoma
  • Avoid in patients with a history of steroid-induced pressure rise

Why it matters

Adherence to postoperative drops is poor in elderly and rural patients, and a single depot takes that out of the equation.

Don't overread it

A 100-eye single-centre trial — too small to establish safety for pressure rise or macular oedema.

The statistics, in plain English

With 50 eyes per group, the trial could show that inflammation scores were similar but could not reliably compare uncommon complications — the pressure spike counts (4 vs 3) are too small to draw conclusions. 'Non-inferior' here reflects no significant difference rather than a formally prespecified margin in the abstract.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

cataractsurgretinauveitispaedophth

Tomorrow morning, before your first patient

One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app